Allovir Stock News

AlloVir, Inc. (ALVR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The mean of analysts' price targets for AlloVir, Inc. (ALVR) points to a 355.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a

WALTHAM, Mass.--( BUSINESS WIRE )--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will

AlloVir, Inc. has some solid data in an area of unmet need. AlloVir is well-capitalized to complete its trials.

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will p

The FDA bestows a third Regenerative Medicine Advanced Therapy designation to AlloVir's (ALVR) lead candidate, posoleucel, for preventing life-threatening infections from six viruses. Shares rise.

The FDA bestows a third Regenerative Medicine Advanced Therapy designation to AlloVir's (ALVR) lead candidate, posoleucel, for preventing life-threatening infections from six viruses. Shares rise.

AlloVir (ALVR) stock is taking off on Wednesday following an update from the U.S. Food and Drug Administration (FDA) on posoleucel. The post Why Is AlloVir (ALVR) Stock Up 30% Today?

AlloVir Inc (NASDAQ: ALVR) shares are trading higher Wednesday after the company announced the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to its l

AlloVir (ALVR) starts a phase III study on its lead candidate, posoleucel, for the prevention of life-threatening viral infections from six common viruses. Shares up.

AlloVir (ALVR) starts a phase III study on its lead candidate, posoleucel, for the prevention of life-threatening viral infections from six common viruses. Shares up.

Zacks Investment Research cut shares of AlloVir from a hold rating to a sell rating in a report published on Friday morning, Zacks.com reports. According to Zacks, “AlloVir…

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 10:00 a.m. EST. A live webcast of the fireside chat will be available on the Investors & Press section of the AlloVir website at https://ir.allovir.com. An archived replay will be availa

AlloVir (NASDAQ: ALVR ) reported its Q4 earnings results on Thursday, February 10, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Check out this: Insiders Buy Over $43M Of 4 Stocks Earnings AlloVir … Full story available on Benzinga.com

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Announces Publication Of Positive Late-Stage Data For Keytruda-Chemo Combo In Breast Cancer Merc